Curated News
By: NewsRamp Editorial Staff
September 08, 2026
Ocumetics Begins Patient Recruitment for Group Two Clinical Study
TLDR
- Ocumetics Technology Corp. advances its clinical trial, positioning for market leadership in accommodating intraocular lenses.
- Ocumetics initiates Group Two recruitment in Mexico City to test safety and vision performance with next-generation lens.
- Ocumetics' lens study moves toward eliminating glasses, improving vision at all distances for patients.
- Ocumetics' new lens uses eye's natural muscles to shift focus, offering clear sight without glasses.
Impact - Why it Matters
This news is crucial for the ophthalmology field and for millions of people who rely on corrective lenses. The Ocumetics Lens promises to provide a full range of vision without glasses or contacts, potentially eliminating the need for them after cataract surgery or as an alternative to LASIK. If successful in clinical trials, this technology could offer a permanent solution for presbyopia and other vision issues, transforming patient quality of life. Moreover, it represents a major step forward in intraocular lens technology, with the potential to disrupt the current market and provide a truly differentiated solution for vision correction.
Summary
Calgary-based Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) has announced the initiation of patient recruitment for Group Two of its human clinical study for its next-generation accommodating intraocular lens, the Ocumetics Lens. The study is taking place at its clinical facility in Mexico City, with surgeries targeted for Fall 2026. This marks a significant step beyond the safety-focused Group One study, as Group Two will evaluate both safety and near-and distance-vision performance. Patients will receive the latest-generation Ocumetics Lens implanted with an enhanced delivery system, reflecting the company's continued technological advancements.
Group One patients are reaching their 12-month follow-ups, providing longer-term clinical data that has been encouraging. The company reports that Group One outcomes met and exceeded expectations regarding safety, performance, and handling. President and CEO Dean Burns expressed excitement about the progress, noting that the Group Two study represents a pivotal milestone in the clinical development of the Ocumetics Lens. The company is also preparing to schedule surgical dates as recruitment completes.
Ocumetics is developing a dynamic intraocular lens designed to fit within the natural lens compartment of the eye, potentially eliminating the need for corrective lenses. The lens aims to allow the eye's natural muscle activity to shift focus from distance to near, providing clear vision at all distances without glasses or contact lenses, and without perceptible time lag. As the company advances through clinical trials, it is moving closer to bringing this transformative technology to market, which could revolutionize vision correction. For more details, view the original release on NEWMEDIAWIRE.
Source Statement
This curated news summary relied on content distributed by NewMediaWire. Read the original source here, Ocumetics Begins Patient Recruitment for Group Two Clinical Study
